Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy
NCT ID: NCT06771193
Last Updated: 2025-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2024-12-17
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study
NCT06150222
Detection of Peritoneal Metastases by Diagnostic LAparoscopy in Patients With Locally Advanced Cervical Carcinoma
NCT06832397
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
NCT07267780
Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras
NCT01651013
Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors
NCT02665494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible cervical cancer patients will be identified by reviewing medical records and physician notes (paper or electronic).
Disease will be defined as follow:
* Locally advanced cervical cancer: a large tumour within the cervix (more than 4cm) or it has grown into the tissues around the cervix, but the cancer has not spread to other organs; usually includes stage 2B, 3 and 4A (FIGO staging)
* Recurrent cervical cancer: local tumour regrowth or development of distant metastasis discovered 6 months or more after complete regression of the treatment (26)
* Metastatic cervical cancer: cancer spreads beyond the pelvis to other parts of the body; usually defined as stage 4B (FIGO staging) Moreover, the patients' characteristics will be stratified as low risk and high risk for locally advanced cervical cancer and differences between their treatment partners will be reported.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years
* Diagnosis of a cervical cancer
* Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease
* Any treatment received between January 2018 and December 2021 for advanced disease
Exclusion Criteria
* Patients who participated in a clinical trial
* Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MSD Italia S.r.l.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oncologia Medica Policlinico Sant'Orsola Malpighi
Bologna, Bologna, Italy
Ginecologia ed Ostetricia A.O. Cannizzaro
Catania, Catania, Italy
Oncologia Medica 1 IRCCS Ospedale Policlinico San Martino
Genova, Genova, Italy
Unità di Ginecologia Oncologica Medica IRCCS Ospedale San Raffaele
Milan, Milano, Italy
Unità Ostetricia, Ginecologia e Ginecologia Oncologica medica Humanitas San Pio X
Milan, Milano, Italy
Oncologia A.O.U. di Modena - Policlinico
Modena, Modena, Italy
U.O.S. Trattamenti Innovativi dell'utero Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale
Napoli, Napoli, Italy
UOC Oncologia Medica ed Ematologia Azienda Ospedaliera Universitaria Luigi Vanvitelli
Napoli, Napoli, Italy
IRCCS Centro di Riferimento Oncologico (CRO)
Aviano, Pordenone, Italy
U.O.C. Ginecologia Oncologica Policlinico Agostino Gemelli
Roma, Roma, Italy
UOC Oncologia Medica Ospedale Dell'Angelo - Mestre Azienda USL3 Serenissima
Mestre, Venezia, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS102062
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.